Monoclonal antibodies recognizing the epidermal growth factor-receptor, cells and methods for producing them and compositions containing them
CA 2116753 C · Owner: Ordonez, Alicia F. · Inventors: Rodriguez, Rolando P.; Bravo, Blanca R. T.; Abraham, Amparo E. M.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to a monoclonal antibodies capable of recognizing the EGF receptor in human placenta or A-431 cells with high affinity and capable of inhibiting EGF binding to the receptor. The monoclonal antibodies also has the ability to produce antibody dependent cellular cytotoxicity; to develop complement-mediated cytotoxic activity; to inhibit tumoral growth in certain cell lines and to show a synergetic effect to inhibit these cell lines proliferation when they are in combination with gangliosides or monoclonal antibodies against EGF.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 1, 1994 and granted September 4, 2001. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended March 1, 2014.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 1, 2016.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.